The Peptide Vaccine of the Future
Annika Nelde1, Hans-Georg Rammensee2, Juliane S Walz3
1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Abstract:
The approach of peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low-side-effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.
Insights
Peptide vaccines show promise for cancer immunotherapy by stimulating immune responses. Further optimization is needed to improve clinical efficacy and integrate this low-side-effect treatment into routine cancer therapy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Peptide-based anticancer vaccination can induce cancer-specific immune responses.
- Clinical responses have been limited, hindering broad applicability.
Purpose of the Study:
- To review current peptide-based vaccine development approaches.
- To discuss critical implications for optimizing peptide vaccine design for improved clinical efficacy.
Main Methods:
- Literature review of studies on peptide-based anticancer vaccination.
- Analysis of factors influencing vaccine design and efficacy.
Main Results:
- Peptide vaccines demonstrate potential but require further refinement.
- Key areas for optimization include antigen selection, adjuvants, and vaccination schedules.
Conclusions:
- Improving peptide vaccine design is crucial for clinical integration.
- Combining peptide vaccines with other therapies and developing predictive biomarkers may enhance efficacy.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
00:42Cross-reactivity